VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 04 01; 384(13):1191-1203.
View in:
PubMed
subject areas
Adenocarcinoma
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
Carcinoma, Squamous Cell
Chemoradiotherapy, Adjuvant
Chemotherapy, Adjuvant
Disease-Free Survival
Double-Blind Method
Esophageal Neoplasms
Esophagogastric Junction
Female
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Middle Aged
Neoadjuvant Therapy
Stomach Neoplasms
authors with profiles
JAFFER A AJANI